Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment
- PMID: 17509027
- DOI: 10.1111/j.1572-0241.2007.01283.x
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment
Abstract
Background and aims: Assessing health related quality of life (HRQOL) is becoming more important in research and clinical care. However, little information is available on the performance of HRQOL questionnaires for the functional bowel disorders (FBD). The aims of this study were to (a) understand the performance of the Sickness Impact Profile (SIP) and IBS-QOL for the functional bowel disorders at baseline and after treatment, (b) determine which HRQOL subscales best improve with treatment, (c) determine clinically meaningful improvement, and (d) determine the predictors of HRQOL at baseline and in response to treatment.
Methods: Women with moderate to severe FBD were evaluated using both medical (desipramine vs placebo) and psychological (cognitive-behavioral therapy vs education) treatments. Clinical and psychosocial questionnaires along with the SIP and IBS-QOL were given at baseline and after 12-wk treatment.
Results: (a) Patients with FBD experience functional limitations in social interactions, home management, and recreational activities, respond emotionally to the pain, feel helpless, out of control, depressed, and irritable, and perceive restrictions in lifestyle relating to toilet accessibility, and eating; (b) HRQOL is not different among the FBD diagnoses or IBS subgroups; (c) the IBS-QOL is more responsive to treatment than the SIP; (d) meaningful clinical improvement is 2.8 points for SIP and 14 for IBS-QOL; and (e) improvement is demonstrated primarily in psychosocial rather than physical domains. In addition, we found that expectation of benefit is greater for taking a pill over a psychological intervention, and the predictive effects of abuse history and pain on outcome is mediated by psychosocial factors.
Conclusions: The data support the value of the IBS-QOL over the SIP, and provide new information on the profile of impairment in FBD, and the ways in which medical and psychological treatments produce improvement in HRQOL.
Similar articles
-
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.Am J Gastroenterol. 2000 Apr;95(4):999-1007. doi: 10.1111/j.1572-0241.2000.01941.x. Am J Gastroenterol. 2000. PMID: 10763950 Clinical Trial.
-
What determines severity among patients with painful functional bowel disorders?Am J Gastroenterol. 2000 Apr;95(4):974-80. doi: 10.1111/j.1572-0241.2000.01936.x. Am J Gastroenterol. 2000. PMID: 10763947
-
Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage.Am J Gastroenterol. 2005 Mar;100(3):664-71. doi: 10.1111/j.1572-0241.2005.30375.x. Am J Gastroenterol. 2005. PMID: 15743366
-
Review article: epidemiology and quality of life in functional gastrointestinal disorders.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:31-9. doi: 10.1111/j.1365-2036.2004.02183.x. Aliment Pharmacol Ther. 2004. PMID: 15521853 Review.
-
Overview of research on health-related quality of life in patients with chronic liver disease.Neth J Med. 2007 Jul-Aug;65(7):227-34. Neth J Med. 2007. PMID: 17656809 Review.
Cited by
-
Psychosocial determinants of irritable bowel syndrome.World J Gastroenterol. 2012 Feb 21;18(7):616-26. doi: 10.3748/wjg.v18.i7.616. World J Gastroenterol. 2012. PMID: 22363132 Free PMC article. Review.
-
The Impact of an Individual Educational Program on the Quality of Life and Severity of Symptoms of Patients with Irritable Bowel Syndrome.Int J Environ Res Public Health. 2020 Jun 13;17(12):4230. doi: 10.3390/ijerph17124230. Int J Environ Res Public Health. 2020. PMID: 32545800 Free PMC article.
-
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report.J Clin Med. 2020 Jul 23;9(8):2353. doi: 10.3390/jcm9082353. J Clin Med. 2020. PMID: 32717980 Free PMC article.
-
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.J Manag Care Spec Pharm. 2021 Apr;27(4):469-477. doi: 10.18553/jmcp.2021.27.4.469. J Manag Care Spec Pharm. 2021. PMID: 33769858 Free PMC article.
-
Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial.BMC Gastroenterol. 2020 Feb 4;20(1):29. doi: 10.1186/s12876-020-1157-z. BMC Gastroenterol. 2020. PMID: 32019509 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous